中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
22期
3377-3378
,共2页
癌,非小细胞肺%吉西他滨%ERCC1基因%疗效%毒性
癌,非小細胞肺%吉西他濱%ERCC1基因%療效%毒性
암,비소세포폐%길서타빈%ERCC1기인%료효%독성
Carcinoma,non-small-cell lung%Gemcitabine%ERCC1 gene%Efficacy%Toxicity
目的 对切除修复交叉互补组l(ERCCl)基因多态性与晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性的相关性进行研究.方法 选取经病理检查确诊的40例非小细胞肺癌患者作为研究对象,抽取静脉血5ml,提取白细胞DNA,采用PCR-RFLP技术对ERCC1 118基因型进行检测,对ERCC1 118基因型与晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性之间的关系进行探讨.结果 患者年龄、性别及病理学类型、临床分期等因素与治疗效果之间差异均无统计学意义(均P＞0.05).C/C基因型频率为55.0％ (22/40),C/T+T/T基因型频率为45.0％(18/40),携带C/C基因的患者有效率为45.5％,携带C/T+WT基因的患者有效率为22.2％,两者有效率差异无统计学意义(x2=2.3488,P＞0.05).结论 ERCC1基因多态性与吉西他滨化疗疗效及毒性之间无明显相关性.
目的 對切除脩複交扠互補組l(ERCCl)基因多態性與晚期非小細胞肺癌患者吉西他濱化療療效及毒性的相關性進行研究.方法 選取經病理檢查確診的40例非小細胞肺癌患者作為研究對象,抽取靜脈血5ml,提取白細胞DNA,採用PCR-RFLP技術對ERCC1 118基因型進行檢測,對ERCC1 118基因型與晚期非小細胞肺癌患者吉西他濱化療療效及毒性之間的關繫進行探討.結果 患者年齡、性彆及病理學類型、臨床分期等因素與治療效果之間差異均無統計學意義(均P＞0.05).C/C基因型頻率為55.0％ (22/40),C/T+T/T基因型頻率為45.0％(18/40),攜帶C/C基因的患者有效率為45.5％,攜帶C/T+WT基因的患者有效率為22.2％,兩者有效率差異無統計學意義(x2=2.3488,P＞0.05).結論 ERCC1基因多態性與吉西他濱化療療效及毒性之間無明顯相關性.
목적 대절제수복교차호보조l(ERCCl)기인다태성여만기비소세포폐암환자길서타빈화료료효급독성적상관성진행연구.방법 선취경병리검사학진적40례비소세포폐암환자작위연구대상,추취정맥혈5ml,제취백세포DNA,채용PCR-RFLP기술대ERCC1 118기인형진행검측,대ERCC1 118기인형여만기비소세포폐암환자길서타빈화료료효급독성지간적관계진행탐토.결과 환자년령、성별급병이학류형、림상분기등인소여치료효과지간차이균무통계학의의(균P＞0.05).C/C기인형빈솔위55.0％ (22/40),C/T+T/T기인형빈솔위45.0％(18/40),휴대C/C기인적환자유효솔위45.5％,휴대C/T+WT기인적환자유효솔위22.2％,량자유효솔차이무통계학의의(x2=2.3488,P＞0.05).결론 ERCC1기인다태성여길서타빈화료료효급독성지간무명현상관성.
Objective To study the efficacy and toxicity related gene polymorphism in non-small cell lung cancer patients with gemcitabine chemotherapy.Methods 40 patients with non-smallcell lung cancer were chosen in the present study.The leukocyte DNA was extracted from blood samples.ERCC1 118 genotypes were detected by PCR-RFLP.The relationship between ERCC1 118 genotype and the chemotherapy efficacy and toxicity of patients received gemcitabine was analyzed.Results The age,gender,pathological type,clinical stage,and other factors had no relation with the treatment effects (P ＞ 0.05).The frequency of C/C genotype was 55.0％ (22/40),the frequency of C/T +T/T genotype was 45.0％ (18/40).The effective rate was 45.5％ in patients carrying the C/C gene,The effective rate was 22.2％ in patients carrying the C/T + T/T gene,the difference between the two groups was not statistically significant (x2 =2.3488,P ＞ 0.05).Conclusion The ERCC1 gene polymorphism is not significantly correlated with the efficacy and toxicity of gemcitabine chemotherapy.
